Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AnaSpec Offers Beta-Amyloid (1-40) and (1-42) Peptides

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
HFIP treated peptides for the advancement of Alzheimer’s disease research.

AnaSpec, EGT Group has provided a whole suite of reagents for the advancement of Alzheimer’s disease (AD) research.

From peptides to assay kits to antibodies to dyes, AnaSpec is the trusted source of integrated proteomics solutions for AD research.

Amongst the more than 300 β-amyloid peptides, we offer β-amyloid (1-40) and (1-42) that are HFIP treated.

β-amyloids are amphiphilic peptides with a hydrophilic N-terminal domain (residues 1 to 28) and a hydrophobic C-terminal (residues 29 to 40-42), the latter corresponding to a part of the transmembrane domain of APP.

β-Amyloid assembly into fibrils is initiated by a conformational transition from random coil to β-sheet (hence the name β-amyloid) and a nucleation-dependent aggregation process.

Aβ peptides that are 39 to 42 amino acid residues in length with a molecular mass of approximately 4 kDa are the core components of neuritic plaques seen in Alzheimer’s disease (AD) brains.

Studies have found that dissolving in HFIP favors alpha helical structure and tends to be monomeric.

HFIP treatment of lyophilized Aβ-peptide results in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AnaSpec Signs Distribution Agreement with Gene X Press
Both company’s announces non-exclusive distributor agreement that will allow Gene X Press to distribute AnaSpec’s catalog and custom products throughout Chile.
Friday, February 18, 2011
AnaSpec Showcases Premium Quality of Fluorescent Nucleic Acid Probes
Company showcases cell-impermeant and cell-permeant nucleic acid stains for detecting nucleic acids for cDNA synthesis and cloning, RNA transcription and transfection.
Wednesday, February 02, 2011
AnaSpec Introduces BAFF Protein
Naïve B-cells when treated with 20-1000 ng/ml BAFF protein shows increased IgG secretion.
Wednesday, October 06, 2010
AnaSpec Signs Distribution Agreement with Bioeasy Diagnostica
Non-exclusive distributor agreement allows Bioeasy to distribute AnaSpec’s catalog and custom products throughout Brazil.
Friday, June 18, 2010
AnaSpec Products Used in Over 400 Patents
As compiled by Google Patent Search, the number of patents citing AnaSpec’s products has passed 400.
Monday, January 25, 2010
AnaSpec to Host Bone Marrow Donor Drive
The company has partnered with AADP to host a bone marrow donor drive on its campus on February 1, 2010.
Tuesday, January 19, 2010
AnaSpec Introduces HiLyte Fluor™ 750
According to company, the new HiLyte Fluor™ 750 dye is the longest-wavelength HiLyte Fluor™ dye currently available.
Monday, January 04, 2010
AnaSpec Signs Distribution Agreement with Bioeksma UAB
The agreement allows Bioeksma UAB to distribute AnaSpec’s catalog and custom products throughout Lithuania and Latvia.
Thursday, June 04, 2009
AnaSpec Launches new Headquarters in Fremont, California
Company announces the launch of its 44,010 square foot facility to offer all top of the line lab/R&D equipment and services.
Wednesday, April 29, 2009
AnaSpec Signs Distribution Agreement with Yope Biotechnology
The non-exclusive distributor agreement allows Yope Biotechnology to distribute AnaSpec’s catalog and custom products throughout China.
Wednesday, December 03, 2008
AnaSpec Establishes new Dedicated GMP Manufacturing Facility
The expansion provides an additional 5000 sq. ft. of GMP space including two class 10,000 clean rooms.
Monday, November 17, 2008
RayBiotech and AnaSpec Sign Licensing Agreement for HiLyte™ Dyes
The licensing agreement allows RayBiotech to label antibodies with AnaSpec HiLytePlus™ and HiLyte Fluor™ dyes and integrate into protein and antibody arrays.
Tuesday, September 16, 2008
AnaSpec and Cyclex Sign Licensing Agreement for Deacetylase Activity Assay Kits
The licensing agreement allows AnaSpec to make, use, and sell deacetylase activity assay kits and the related products.
Monday, September 15, 2008
Novus Biologicals and AnaSpec Sign Licensing Agreement for HiLyte™ Dyes
The licensing agreement allows Novus to label Novus antibodies with AnaSpec HiLytePlus™ and HiLyte Fluor™ dyes.
Tuesday, July 29, 2008
AnaSpec’s Published References Passes 600
As compiled by Stanford University’s Highwire Press, the number of published papers that cite AnaSpec’s products has passed 600.
Monday, May 05, 2008
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!